Iranian clozapine versus leponex

Iranian clozapine versus leponex in the treatment of the positive negative symptoms of schizophrenia: a double-blind randomized crossover trial.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT201010042935N4

Enrollment

Registered

2010-10-28

Start date

2010-07-09

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

schizophrenia. Schizophrenia

Interventions

Intervention 1: Iranian clozapine (Tehran shimi company) 100 mg TDS for 3 months. Intervention 2: leponex (manufactured by Novartis pharmaceutical company-Switzerland) 100 mg tid for 3 months.

Treatment - Drugs

Iranian clozapine (Tehran shimi company) 100 mg TDS for 3 months

leponex (manufactured by Novartis pharmaceutical company-Switzerland) 100 mg tid for 3 months

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: Inclusion Criteria: diagnosis of Schizophrenia based on DSM IV, chronic Schizophrenia, resistant schizophrenia (no response to two different antipsychotics at past) Exclusion Criteria: Substance dependence, any serious medical problem, development of agranulocytosis or seizure during treatment with clozapine

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Severity of schizophrenia. Timepoint: Baseline and 3 and 6 months after beginnig of the treatmen. Method of measurement: Positive and Negative Syndrome Scale (PANSS).	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Farzin Rezaei

Kurdistan University of Medical Sciences

farrezaei@muk.ac.ir; Farzin.Rezaie@uok.ac.ir ; frrezaie@yahoo.com+98 87 1666 0025

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026